Filing Details
- Accession Number:
- 0001193125-22-042050
- Form Type:
- 13G Filing
- Publication Date:
- 2022-02-13 19:00:00
- Filed By:
- Quested Robert
- Company:
- Silence Therapeutics Plc
- Filing Date:
- 2022-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Robert Quested | 7,004,127 | 0 | 7,004,127 | 0 | 7,004,127 | 7.81% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ) *
Silence Therapeutics plc
(Name of Issuer)
Ordinary Shares, par value £0.05 per share
(Title of Class of Securities)
G8128Y157
(Cusip Number)
December 31, 2021
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☐ | Rule 13d-1(c) |
| ☒ | Rule 13d-1(d) |
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)
Page 1 of 4 Pages
13G
CUSIP No. G8128Y157
| 1 | NAMES OF REPORTING PERSONS
Robert Quested | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ☐ (b) ☐
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
7,004,1271 | ||||
| 6 | SHARED VOTING POWER
0 | |||||
| 7 | SOLE DISPOSITIVE POWER
7,004,1271 | |||||
| 8 | SHARED DISPOSITIVE POWER
0 | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,004,1271 | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.81%1 | |||||
| 12 | TYPE OF REPORTING PERSON (See Instructions)
IN | |||||
| 1 | Consisting of 7,004,127 Shares represented by ADSs (as defined in the Preliminary Note). |
Preliminary Note:
As of the date of this report, Mr. Quested beneficially owns an aggregate of 2,334,709 American Depositary Shares (ADSs), each of which represents, and at the holders option is convertible into, three Shares.
| Item 1. | Issuer |
| (a) | Name of Issuer: |
Silence Therapeutics plc (the Company)
| (b) | Address of Issuers Principal Executive Offices: |
77 Hammersmith Road
London W14 8TH
United Kingdom
| Item 2. | Identity and Background |
Title of Class of Securities and CUSIP Number (Items 2(d) and (e))
This statement relates to ordinary shares, par value £0.05 per share (the Shares), of the Company. The CUSIP number of the Shares is G8128Y157.
Name of Persons Filing, Address of Principal Business Office and Citizenship (Items 2(a), (b) and (c))
This statement is filed on behalf of Robert Quested (the Reporting Person).
The address of the Reporting Person is: The Anchorage, Gibraltar, GX1 1AA.
| Item 3. | If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is an Entity Specified in (a) - (k): |
Not applicable.
| Item 4. | Ownership |
The percentages used herein and in the rest of this Schedule 13G are calculated based upon 89,777,000 Shares issued and outstanding at 30th September 2021, as disclosed in the Companys Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on 16 November 2021.
| (a) | Amount beneficially owned: 7,004,127 Shares |
| (b) | Percent of class: 7.81% |
| (c) | (i) Sole power to vote or direct the vote: 7,004,127 |
| (ii) | Shared power to vote or direct the vote: 0 |
| (iii) | Sole power to dispose or direct the disposition: 7,004,127 |
| (iv) | Shared power to dispose or direct the disposition of: 0 |
| Item 5. | Ownership of Five Percent or Less of a Class |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be a beneficial owner of more than five percent of the class of securities, check the following: ☐
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
Not applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person |
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
| Item 9. | Notice of Dissolution of Group |
Not applicable.
| Item 10. | Certification |
Not applicable.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2022
Robert Quested
| By: | /s/ Robert Quested | |
| Name: Robert Quested | ||